J
Jay D. Amsterdam
Researcher at University of Pennsylvania
Publications - 286
Citations - 16973
Jay D. Amsterdam is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Placebo & Fluoxetine. The author has an hindex of 67, co-authored 283 publications receiving 16005 citations. Previous affiliations of Jay D. Amsterdam include University of California, Irvine & Wistar Institute.
Papers
More filters
Journal ArticleDOI
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Jay C. Fournier,Robert J. DeRubeis,Steven D. Hollon,Sona Dimidjian,Jay D. Amsterdam,Richard C. Shelton,Jan Fawcett +6 more
TL;DR: The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms.
Journal ArticleDOI
Cognitive therapy vs medications in the treatment of moderate to severe depression.
Robert J. DeRubeis,Steven D. Hollon,Jay D. Amsterdam,Richard C. Shelton,Paula R. Young,Ronald M. Salomon,John P. O'Reardon,Margaret L. Lovett,Madeline M. Gladis,Laurel L. Brown,Robert Gallop +10 more
TL;DR: Cognitive therapy can be as effective as medications for the initial treatment of moderate to severe major depression, but this degree of effectiveness may depend on a high level of therapist experience or expertise.
Journal ArticleDOI
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
Steven D. Hollon,Robert J. DeRubeis,Richard C. Shelton,Jay D. Amsterdam,Ronald M. Salomon,John P. O'Reardon,Margaret L. Lovett,Paula R. Young,Kirsten L. Haman,Brent B. Freeman,Robert Gallop +10 more
TL;DR: Cognitive therapy has an enduring effect that extends beyond the end of treatment and seems to be as effective as keeping patients on medication.
Journal ArticleDOI
The International Society for bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders
Isabella Pacchiarotti,David J. Bond,Ross J. Baldessarini,Willem A. Nolen,Heinz Grunze,Rasmus Wentzer Licht,Robert M. Post,Michael Berk,Guy M. Goodwin,Gary S. Sachs,Leonardo Tondo,Robert L. Findling,Eric A. Youngstrom,Mauricio Tohen,Juan Undurraga,Ana González-Pinto,Joseph F. Goldberg,Aysegul Yildiz,Lori L. Altshuler,Joseph R. Calabrese,Philip B. Mitchell,Michael E. Thase,Athanasios Koukopoulos,Francesc Colom,Mark A. Frye,Gin S Malhi,Konstantinos N. Fountoulakis,Gustavo H. Vázquez,Roy H. Perlis,Terence A. Ketter,Frederick Cassidy,Hagop S. Akiskal,Jean-Michel Azorin,Marc Valentí,Diego Hidalgo Mazzei,Beny Lafer,Tadafumi Kato,Lorenzo Mazzarini,Anabel Martínez-Arán,Gordon Parker,Daniel Souery,Ayşegül Özerdem,Susan L. McElroy,Paolo Girardi,Michael Bauer,Lakshmi N. Yatham,Carlos A. Zarate,Andrew A. Nierenberg,Boris Birmaher,Shigenobu Kanba,Rif S. El-Mallakh,Alessandro Serretti,Zoltán Rihmer,Allan H. Young,Georgios D. Kotzalidis,Glenda MacQueen,Charles L. Bowden,S. Nassir Ghaemi,Carlos López-Jaramillo,Janusz K. Rybakowski,Kyooseob Ha,Giulio Perugi,Siegfried Kasper,Jay D. Amsterdam,Robert M. A. Hirschfeld,Flávio Kapczinski,Eduard Vieta +66 more
TL;DR: A consensus was reached on 12 statements on the use of antidepressants in bipolar disorder, and antidepressants should be prescribed only as an adjunct to mood-stabilizing medications.
Journal ArticleDOI
Treatment resistant depression: methodological overview and operational criteria.
Daniel Souery,Jay D. Amsterdam,C de Montigny,Yves Lecrubier,Stuart Montgomery,Olivier Lipp,Giorgio Racagni,Joseph Zohar,Julien Mendlewicz +8 more
TL;DR: The proposed criteria are intended for therapeutic trials in TRD, combining the evaluation of treatment efficiency and the validation of the concept of TRD itself, including major depression with poor response to two adequate trials of different classes of antidepressants.